nivolumab,Sintilimab
bms,eli lilly
['cm816']
 unfortunate trial was terminated early as the difference was not statistically significant. also, squam having higher mpr was not seen in cm816. question of just not enough patients or difference in biology with different populations?
Director, thoracic oncology @Intermountain. medical oncologist, interested in quality improvement, end-of-life care. tweets my own.